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Abstract
Type 1 diabetes mellitus (T1DM) is an autoimmune disease caused by immune-mediated destruction of insulin-secreting b
cells of the pancreas. Near complete dependence on exogenous insulin makes T1DM very difficult to control, with the result
that patients are exposed to high blood glucose and risk of diabetic complications and/or intermittent low blood glucose
that can cause unconsciousness, fits and even death. Allograft transplantation of pancreatic islets restores normoglycemia
with a low risk of surgical complications. However, although successful immediately after transplantation, islets are
progressively lost, with most of the patients requiring exogenous insulin within 2 years post-transplant. Therefore, there is
an urgent requirement for the development of new strategies to prevent islet rejection. In this study, we explored the
importance of human regulatory T cells in the control of islets allograft rejection. We developed a pre-clinical model of
human islet transplantation by reconstituting NOD-scid IL2rcnull mice with cord blood-derived human CD34+ stem cells and
demonstrated that although the engrafted human immune system mediated the rejection of human islets, their survival
was significantly prolonged following adoptive transfer of ex vivo expanded human Tregs. Mechanistically, Tregs inhibited the
infiltration of innate immune cells and CD4+ T cells into the graft by down-regulating the islet graft-derived monocyte
chemoattractant protein-1. Our findings might contribute to the development of clinical strategies for Treg therapy to
control human islet rejection. We also show for the first time that CD34+ cells-reconstituted NOD-scid IL2rcnull mouse model
could be beneficial for investigating human innate immunity in vivo.
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Introduction
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune
disease in which insulin-secreting pancreatic b cells are destroyed
by autoreactive T cells. It is characterized by dysregulation of
blood glucose caused by b -cell insufficiency. Among the available
treatments, human islet transplantation has emerged as a
promising approach that restores glycemic stability even if full
discontinuation of insulin treatment is not practical [1–3].
Transplanted islets, which consist of small clusters of cells
containing insulin-producing b-cells, however provoke the same
immunological responses as solid organ transplants, and necessi-
tate immunosuppressive therapy to reduce immune-mediated
rejection [4]. Immunosuppressive drugs have severe side effects,
and they are toxic to b-cells as well as being ineffective at
preventing late-stage allograft rejection [5,6]. To achieve durable
success in islet transplantation, there is a need to develop
applicable strategies for immunomodulation in order to suppress
T cell-mediated alloimmune responses [7–10].
CD4+CD25hiFoxP3+ regulatory T cells (Tregs) have been shown
to be important for the control of autoimmunity and maintenance
of allograft tolerance [7]. In humans, normally only 5–10% of
peripheral blood CD4 T cells are natural-occurring regulatory T
cells [11] and thus large-scale ex vivo expansion is required for
therapeutic application [12]. We and others have recently shown
that large-scale ex vivo expanded human Tregs maintain their
immunosuppressive capacity and are stable in vitro and in vivo under
inflammatory conditions and are safe for clinical use [13–16]. This
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raises the possibility that Tregs may be used in islet transplantation
to protect human grafted islets from alloimmune rejection without
the side effects of systemic immunosuppression.
The recent development of ‘humanized’ mice has allowed the
in vivo investigation of human immune responses [17–20]. In
transplantation models, we and others have demonstrated that ex
vivo expanded human Tregs can prevent the development of
transplant arteriosclerosis [21] and skin allograft rejections [22] in
peripheral blood mononuclear cells (PBMC)-reconstituted human-
ized mouse models [23]. The protective function of adoptively
transferred human Tregs has also been investigated in PBMC-
reconstituted humanized mouse transplanted with porcine islets.
More recently, Douglas et al. have shown that human Tregs can
prevent human islet transplant rejection by inhibiting T cell
differentiation in PBMC-reconstituted Balb/cRag22/2cc2/2
mouse model [24]. In the present study, we adoptively transferred
ex vivo expanded human Tregs into CD34
+ stem cells-reconstituted
NOD-scid IL2rcnull (NSG) mice to determine whether Tregs can
protect grafted human islets from immune-mediated rejection,
focusing primarily on the effects of Tregs on the innate immune
responses.
Materials and Methods
Ethics statements
Use of human peripheral blood from healthy volunteers (REC
Ref: 09/H0707/86), cord blood from full-term deliveries (REC
Ref: 08/H0802/160) and islets from cadaveric donors (REC Ref:
05/MER09/48) has been approved by the National Research
Ethics Service Committee London - Westminster, UK. Blood
donors and the relatives of islet donors gave written informed
consent for scientific use of the human materials. All consent
procedures were approved by the National Research Ethics
Service Committee London - Westminster, UK.
All animal experiments were conducted in accordance with UK
Research Councils’ and Medical Research Charities’ guidelines on
Responsibility in the Use of Animals in Bioscience Research, and
the Home Office Animals Scientific Procedures Act (1986) under a
UK Home Office license (PPL 70/7302). Anesthetics and
analgesics were administered to minimize or eliminate the pain
and distress appropriately.
Isolation of CD34+ stem cells from human umbilical cord
blood
Cord blood was supplied by the NHS Cord Blood Bank
(Colindale, London, UK). Mononuclear cells were isolated using
density gradient centrifugation over Ficoll-Paque (GE Healthcare,
Hatfield, UK) and enriched for CD34+ cells by positive
immunomagnetic isolation according to the manufacturer’s
instructions (Miltenyi Biotech, Surrey, UK).
Reconstitution of mice with human stem cells
NSG mice (The Jackson Laboratory) were bred and maintained
in the Biological Services Unit of King’s College London under
specific pathogen-free conditions. Mice of 4–6 week old were
irradiated with 240 cGy of c-rays and received intravenous
injection of 26105 CD34+ stem cells within 24 hours (Fig. 1A).
For simplicity, the CD34+ cells-reconstituted NSG mice are
hereafter referred to as hu-NSG mice and NSG mice lacking
CD34+ cells injection are referred to as NSG mice.
Preparation of human regulatory T cells
Human leukocyte cones were obtained from the National Blood
Transfusion Service (Tooting, London, UK). PBMC were isolated
by Lymphocyte (PAA, Austria) density gradient centrifugation.
CD4+CD25+ T cells (Tregs) were isolated from PBMC using a
CD4+CD25+ Regulatory T Cell Isolation Kit (Miltenyi Biotec)
according to the manufacturer’s instructions. The CD4+CD252
cells (Teffs) were used as autologous responder cells for in vitro
suppression assays. Isolated Tregs were expanded as previously
published [14]. Briefly, Tregs were cultured in X-vivo 15 medium
(Lonza, Slough, UK) supplemented with 5% of human AB male
pooled serum (HS, Biosera, London, UK), in the presence of
recombinant IL-2 (1000 IU/mL, Proleukin-Novartis, Surrey,
UK), rapamycin (100 nM) (Sigma, Surrey, UK) and Human T-
Expander CD3/CD28 Dynabeads (CD3/CD28 beads, Invitro-
gen, Paisley, UK) in a 1:1 cell to bead ratio for three rounds of
expansion, 8–10 days each. After the third round of expansion, the
beads were removed and the Tregs were rested for 5–7 days in
medium containing low concentration of IL-2 (20 IU/mL) before
being intravenously injected into the mice.
T cell proliferation assay
Cell suspensions (16105) prepared from the spleen of hu-NSG
mice were cultured in 10% FBS RPMI-1640 medium in the
presence of CD3/CD28 beads at a 1:1 bead to cell ratio. T-cell
proliferation was measured after a 72 hour culture by adding 3H
thymidine (1 mM) for the last 16 hours. In a mixed lymphocyte
reaction (MLR), human CD4+ cells isolated from the spleen of hu-
NSG mice immunized by HLA-mismatched PBMC were co-
cultured with serial dilutions of irradiated [3000 gray (Gy) for
10 min] PBMC from the same donor (specific PBMC) and the
PBMC from an unrelated donor (third-party PBMC). The
proliferation assays were performed in a five day culture.
The suppressive activity of expanded Tregs was tested by co-
culturing responder T cells (CD4+CD252, Teffs) labelled with
5 mM carboxyfluorescein succinimidyl ester (CFSE, Invitrogen)
with serial dilutions of ex vivo expanded autologous Tregs in the
presence of CD3/CD28 beads in a 1:1 Teffs to bead ratio in
RPMI-1640 medium containing 10% of human AB serum for 5
days. Proliferation was analyzed by flow cytometry. The percent-
age of proliferative Teffs in the absence of Tregs was taken as 100%
proliferation.
Islet transplantation and adoptive transfer of Tregs
Hu-NSG and NSG mice were rendered diabetic (blood glucose
level$20 mM) by a single intraperitoneal (i.p.) injection of
streptozotocin (STZ), 180 mg/kg body weight. Human islets were
obtained from King’s Cell Isolation Unit (London, UK). All islets
were maintained in CMRL 1066 culture medium (Invitrogen)
containing 2.5% human albumin at 37uC in an atmosphere of
95% air 5% CO2 until transplanted. Human islet equivalents
(IEQs, 3000–4000) were then transplanted under the left kidney
capsule of diabetic mice that were anesthetized with pentobarbital
sodium at 50 mg/kg [25]. After surgery, the mice were given
subcutaneously 0.03 mg/ml of Vetergesic Multidose (buprenor-
phine) (Alstoe Ltd. Animal Health, UK) in 100 ml of sterile saline
for post-operative analgesia. A total of 66106 ex vivo expanded
human Tregs expressing the same HLA-DR as the engrafted
CD34+ stem cells (Table S1) were injected intravenously into
recipient mice immediately after islet transplantation. Blood
glucose levels in recipient mice were evaluated using a blood
glucose sensor (Abbott Diabetes Care Ltd., Witney, Oxon, UK).
Loss of graft function was determined by blood glucose
values$20 mM.
Human Tregs Delay Islet Allograft Rejection
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Nephrectomy
Selected mice with successful islet transplants were subjected to
unilateral left nephrectomy to evaluate a return to hyperglycemic
states. Anaesthetized mice were placed in a lateral decubitas
position and a 2 cm incision was made over the left flank. The
kidneys were extracorporealized. The renal artery was ligated
together with the vein and ureter, prior to kidney resection. All
animals were monitored closely postoperatively, and blood glucose
was measured every 24 hours for 5 days.
Flow cytometric analysis
Flow cytometric analysis of human antigens in human Tregs and
leukocytes was performed as previously described [26]. Fluoro-
chrome-coupled antibodies specific for human CD45, CD3,
CD19, CD45RA, CD45RO, CD4, CD25, FoxP3, CD14,
CD11C, CD16 and CD56 were used for analysis of the human
cell engraftment in hu-NSG mice. An APC-conjugated antibody
against human monocyte chemoattractant protein-1 (MCP-1) was
used for the detection of MCP-1 expression in islet cells. Single cell
suspensions from the draining lymph nodes (left renal) and spleens
were prepared from the islet-transplanted hu-NSG mice at the
time of rejection (islets alone group) or at 21 days post-
transplantation (islets+Tregs group), and stained with antibodies
against human CD4, CD25 and FoxP3. Flow cytometric data
were acquired using a FACS Calibur (BD Biosciences, San Jose,
CA, USA) and analyzed using FlowJo 7.5 software (TreeStar Inc.).
Co-culture of human islets and Tregs
The human islets were dissociated into single cells with 0.05%
trypsin-EDTA. The single cells (0.5 million cells) were cultured
with or without 1 million ex vivo expanded Tregs in the presence of
CD3/CD28 beads in 10% HS RPMI-1640 medium for 48 hours.
LPS (1 mg/mL) was then added to the cultures for an additional
24 hours. As a control, the islets were co-cultured with autologous
Teffs under the same conditions. After the incubation period, Tregs
or Teffs were positively isolated using CD4 Dynabeads (Invitrogen).
The eluted fraction was used for flow cytometric analysis and real-
time RT-PCR for expression of MCP-1.
Real-time RT-PCR
PCR primers specific for human MCP-1 were designed as
previously published [27] and RNA was extracted from islet grafts
Figure 1. Reconstitution of NSG mice with human CD34+ stem cells. (A) Strategy for generation of humanized mouse model of islet
transplantation. (B) A representative FACS profile of human CD45+, human CD19+ and human CD3+ cells in peripheral blood of hu-NSG mice, 12–16
weeks after transfer of CD34+ cells (n = 15). Human CD19+ B cells and CD3+ T cells were identified in the gate for human CD45+ cells. (C) Splenocytes
from hu-NSG mice were analyzed by FACS for human CD45RA+ (naı¨ve T cells), human CD45RO+ (memory T cells), human CD4+CD25+FoxP3+ (Tregs),
human CD11c+ (dendritic cells), human CD14+ (macrophages) and human CD16+CD56+ (NK cells) expression. (D–E) Data are summarized. Plotted
lines represent the mean (n = 15, D; n = 3, E).
doi:10.1371/journal.pone.0090387.g001
Human Tregs Delay Islet Allograft Rejection
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harvested at the time of rejection (islets alone group) or at 21 days
post-transplantation (islets+Tregs group) and from cultured single
islet cells using RNeasy Mini Kit (Qiagen). Real-time RT-PCR
was performed using Brilliant SYBR Green QRT-PCR Master
Mix Kit, following the manufacturer’s protocol (Agilent Technol-
ogies, UK).
Enzyme-linked immunosorbent assay (ELISA) for human
IgG, IgM, insulin and complement 3 (C3)
Human IgM and IgG were measured in the serum of hu-NSG
mice over 12–16 weeks after the CD34+ stem cells injection, and
then anti-keyhole limpet hemocyanin (KLH) IgM and IgG were
measured two weeks after hu-NSG mice were immunized with
KLH whole protein (Sigma), using standard ELISA protocols (11).
Mouse sera taken from islet-transplanted hu-NSG mice at the
time points when blood glucose was 7, 20 and 28 mM were
assessed for human insulin and sera taken at the time of islet
allograft rejection (blood glucose.20 mM) were determined for
human C3 by ELISA kits (Millipore, Watford, UK).
Cytokine detection
Human Th1/Th2 cytokines were determined in the superna-
tants of CD4+ T cells isolated from the spleen cells of hu-NSG
mice after a 3 day stimulation by CD3/CD28 beads, and in the
serum samples harvested at the time of rejection (islets alone
group) or at 21 days post-transplantation (islets+Tregs group). A
human Th1/Th2 11plex kit (eBiosciences) was used according to
the manufacturer’s protocol. Data acquisition was performed on a
FACS Calibur (BD Biosciences) and then was analyzed using the
BD Cytometric Bead Array software (BD Biosciences). The
cytokines detected were IFN-c, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-
8, IL-10, IL-12p70, TNF-a and TNF-b.
Histological and immunohistochemical analysis
Graft-bearing kidneys were harvested, fixed in 10% buffered
formalin, and embedded in paraffin at the time of rejection (islets
alone group) or at 21 days post-transplantation (islets+Tregs group).
Sections (5 mm) were conventionally processed and stained with
hematoxylin and eosin (H&E). For characterization of cell type-
specific expression of antigens, single immunofluorescence staining
was used: after antigen retrieval by microwaving for 5 min in
0.01 M citrate buffer (pH 6.0), sections were blocked with 10%
goat normal serum for 30 min and then incubated overnight at
4uC with primary antibodies against the following: human CD45
(1:50; Dako, clone 2B11+PD7/26), insulin conjugated with HRP
(1:50; Abcam, clone D3E7), complement 3d (C3d) conjugated with
HRP (1:60; Dako, polyclonal), human CD4 (1:40; Dako, clone
4B12), human CD8 (1:60; Abcam, clone 14), human CD11b (1:50;
eBiosciences, clone ICRF44) and human CD66b (1:50; BioLe-
gend, clone G10F5). Diaminobenzidene and FITC- or TRITC-
conjugated secondary antibodies were applied for 2 hours at room
temperature. Sections were mounted in ProLong Gold Antifade
Reagent with DAPI (Invitrogen). For identification of Tregs, slides
were double stained with primary antibodies: mouse anti-human
CD4 and rabbit anti-human FoxP3 (1:60; both Abcam, polyclon-
al). FITC-conjugated goat anti-mouse IgG and TRITC-conjugat-
ed goat anti-rabbit IgG (both Sigma) were used as secondary
antibodies. Negative controls with nonspecific IgG were processed
in parallel. Images were acquired using a Cooled Mono14 Bit
camera (Q IMAGING, Canada) and Micro-Manager 1.3 software
(University of California, USA).
Statistics
All statistical analysis were performed using the two-tailed
Student’s t-test (unpaired) for the group data and log-rank test for
the survival data (Prism 4.0; GraphPad Software, USA). Data were
presented as means 6 SD and P values,0.05 were considered
significant.
Results
NSG mice reconstituted with human CD34+ stem cells
are engrafted with a functional human immune system
A number of humanized mouse models have been generated for
the in vivo study of human immune responses [28,29]. Here, NSG
mice of 4-6 weeks of age were injected with cord blood-derived
CD34+ stem cells (Fig. 1A). After 3 months, a significant
percentage of human cells was identified by flow cytometric
analysis in the blood of NSG recipients (36%65%) with 1:1 ratio
of T and B cells (Fig. 1B and D). Various subsets of immune cells
were present in the spleens of these animals, including naı¨ve T cells
(CD45RA+), memory T cells (CD45RO+), Tregs (CD4
+CD25+
FoxP3+), macrophages (CD14+), dendritic cells (CD11c+) and NK
cells (CD16+CD56+) (Fig. 1C and E).
To validate the function of engrafted T cells, splenocytes from
hu-NSG mice were stimulated in vitro with anti-CD3/CD28 beads.
T cells responded to polyclonal stimulation (Figure S1 (A)) and
the cytokines IL-2, TNF-a, TNF-b, IL-8 and IL-1b were detected
in culture supernatants (Table 1). Next, human CD4+ T cells
from the spleens of hu-NSG mice that had been immunized in vivo
with allogeneic PBMC (specific PBMC) (Figure S1 (B)) were re-
stimulated in vitro with specific PBMC or with third party PBMC.
These CD4+ T cells showed significant responses to the specific
PBMC, but not to third party PBMC (Figure S1 (B)).
The function of B cells in hu-NSG mice was also evaluated and
both IgM and IgG were detected in sera (IgM: 76.6761.45 mg/
mL; IgG: 44.3969.4 mg/mL) (Figure S2 (A)) and in supernatants
after culturing B cells in vitro in the presence of IL-2 and IL-21
(IgM: 0.3760.013 mg/mL; IgG: 0.9960.21 mg/mL) (Figure S2
(A)). Furthermore, KLH-specific IgM responses, but not IgG, were
induced in vivo after KLH immunization (Figure S2 (B)), as
previously observed [26,30].
Table 1. Cytokine production by human CD4 T cells from
hu-NSG mice in vitro.
Spl:CD4 AdPBMC:CD4
Pg/mL Control CD3/CD28 Control CD3/CD28
IFN-c ud* ud ud 168.5697.27
IL-2 ud 298.58620.26 ud 1750.186223.93
TNF-a ud 62.3066.86 ud 1197.476192.22
TNF-b 7.7562.62** 118.62621.35 5.9862.45 510.9689.35
IL-10 ud ud ud 201.91639.45
IL-8 101.83634.39 150.4169.21 73.54622.63 1871.146318.04
IL-1b 2.5261.45 0.6360.36 3.1761.83 10.9866.33
Human CD4+ T cells were stimulated with CD3/CD28 beads for three days.
Supernatants were analyzed by cytometric bead array for cytokine production
(n = 3). Cytokines IL-4, IL-5, IL-6 and IL-12p70 were not detectable in the
supernatants. Spl:CD4 denotes CD4 cells from the spleen of a hu-NSG mouse.
AdPBMC:CD4 indicates CD4 cells from PBMC of a healthy donor.
*: undetectable. **: mean 6 SD.
doi:10.1371/journal.pone.0090387.t001
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Human islet allografts stimulate immune responses in
hu-NSG mice
Having confirmed that hu-NSG mice had a functional adaptive
immune response, although partially impaired [26,30,31], mice
with successful human cell engraftment (human CD45+
cells.15%) were rendered diabetic. They were then transplanted
with human IEQs (3000-4000) under the kidney capsule. This
resulted in immediate establishment of normoglycemia (blood
glucose,13.8 mM) [24,32]. Islet allograft rejection, as evidenced
by a rise in blood glucose above 20 mM, was observed in all hu-
NSG mice by day 17 post-transplantation while normoglycemia
remained stable over an observation of 90 days in NSG mice (6
animals for each group) (Fig. 2A). In order to demonstrate the
functionality of transplanted islets in vivo, six mice with successful
islet transplantations were selected to undergo unilateral left
nephrectomy, which restored a hyperglycemic state within
24 hours (Figure S3). Human insulin levels in the sera from islet
transplanted-hu-NSG mice correlated negatively with the levels of
blood glucose (Fig. 2B).
Immune responses stimulated by islet allografts were analyzed
in the sera and by histology at the time of rejection. Significant
amounts of human C3 were detected in the sera of hu-NSG mice
with islet transplants, but not in hu-NSG mice lacking islet
transplants or in NSG mice with or without islet transplants
(Fig. 3A). Human cytokines, including IFN-c, IL-4 and IL-1b,
were detected at pg/mL levels in the sera from the islet
transplanted-hu-NSG mice but not in the hu-NSG without islet
transplants (Fig. 3B). Histological analysis revealed damaged islet-
structures with fewer insulin positive cells in mice with rejecting
allografts (Fig. 4c and g). A large number of graft-infiltrating
mononuclear cells (Fig. 4e, f and i) and human CD45+ cells
(Fig. 4h) were detected in hu-NSG recipients, but not in NSG
mice (Fig. 4a, b and d). A significant number of macrophages
(CD11b+), neutrophils (CD66b+) and CD4+ T cells were recruited
into the graft-bearing kidney tissue in hu-NSG mice (Fig. 4l, m
and j). Very few, if any, CD8+ T cells were identified in hu-NSG
mice (Fig. 4k). C3d deposition in the islet grafts was also observed
(Fig. 4n). Altogether these results indicate that hu-NSG mice
mount both innate and adaptive immune responses against
transplanted human islet allografts.
Ex vivo polyclonally expanded human Tregs delay
human islet allograft rejection
Next, we investigated the impact of Tregs on the modulation of
human islet allograft rejection. Human Tregs (CD4
+CD25+) were
isolated and expanded in vitro in the presence of rapamycin and IL-
2 [14]. The Treg lines were characterized phenotypically and
functionally, prior to adoptive transfer into recipient mice. Flow
cytometric analysis revealed that greater than 98% of CD4-gated
Tregs expressed high levels of CD25 and FoxP3 (Figure S4 (A)).
Tregs displayed a marked suppressive ability as measured by CFSE
dilution (Figure S4 (B) and (C)).
Treg lines (6610
6) were then injected intravenously into hu-NSG
mice at the time of islet transplant. Islet graft survival was
monitored by measuring blood glucose levels in the sera of the
mice. The results demonstrated that the transfer of ex vivo
expanded Tregs prolonged the survival of islets (median survival
time Tregs-treated mice 32 days versus 17 days in mice receiving
islets alone) (n = 15 for islets alone group; n = 10 for islets+Tregs
group; Fig. 5A). To confirm that the prolonged graft survival was
the result of Treg-mediated suppression, islet grafts were harvested
at the time of graft-rejection for Treg-untreated recipients and at
day 21 post-transplantation (animals with grafts undergoing
rejection were excluded) for Treg-treated recipients. Histological
analysis demonstrated that surviving grafts contained densely
packed insulin-producing cells and intact islet structures, whereas
grafts undergoing rejection exhibited destroyed lobular structure
of islets with few remaining insulin positive-staining cells (Fig. 5B).
The numbers of macrophages (CD11b+), neutrophils (CD66b+)
and CD4+ T cells infiltrating the grafts were markedly reduced in
Treg-treated animals, compared with Treg-untreated recipients
(n = 3 for each group) (Fig. 5B and C). These results suggest a
potent suppression of innate and CD4+ T cell-mediated immune
responses by Tregs. The improved histology correlated with the
presence of Tregs (CD4
+FoxP3+) in the graft of Treg-treated
animals (Fig. 5D) and higher numbers of Tregs in the draining
lymph nodes (Fig. 6A). Lower numbers of total CD4+ T cells were
observed in the spleens and draining lymph nodes of these mice
compared to Treg-untreated mice (Fig. 6B and C), whereas no
significant differences were found in the number of
Figure 2. Diabetic hu-NSG mice reject the grafted human islets. (A) The function of grafted human islets was evaluated by measuring blood
glucose levels. As a control, NSG mice without CD34+ cell reconstitution remained normoglycemic after islet transplantation. The insert shows a
representative image of a kidney and a spleen from hu-NSG mice that received (bottom) or did not receive (top) islet transplants (n = 6). STZ:
streptozotocin. (B) Serum samples from hu-NSG mice that were grafted with human islets were measured by ELISA for human insulin when blood
glucose was 7, 20 and 28 mM (n = 3).
doi:10.1371/journal.pone.0090387.g002
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Figure 3. Human innate and adaptive immune responses mediate islet rejection in the hu-NSGmice. (A) Sera were analyzed by ELISA for
human C3 levels in hu-NSG mice with/without human islet transplants or NSG mice with/without transplants (n = 3). Control: no islet transplant. (B)
Sera were collected at the time of graft rejection. Cytokines were measured by cytokine bead array (n = 3). Control: sera from hu-NSG mice without
islet transplant. *: undetectable. **: mean 6 SD.
doi:10.1371/journal.pone.0090387.g003
Figure 4. Infiltration of immune cells and C3 deposit in the grafted human islets. Tissue samples of islet allograft bearing kidney in hu-NSG
mice were collected at the time of islet allograft rejection. Sections were stained with H & E (a–b, e–f and i) and antibodies to human antigens:
insulin (c and g, brown), CD45 (d and h, green), CD4 (j, green), CD8 (k, red), CD11b (l, green), CD66b (m, red), and C3d (n, brown). Arrow indicates
the kidney capsule or the area around islet grafts. Red square indicates the site of the infiltration. Scale bar: 100 mm.
doi:10.1371/journal.pone.0090387.g004
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CD4+CD25+FoxP3+ cells in the spleens between the two groups of
mice (Fig. 6A).
Ex vivo expanded human Tregs down regulate MCP-1
expression by islets
Having observed a decreased infiltration of macrophages
(CD11b+) and neutrophils (CD66b+) in the islet grafts of hu-
NSG mice and an increase in Tregs in the draining lymph nodes
following adoptive transfer of Tregs, we chose to focus on the
mechanisms behind the regulation of innate cell infiltration.
Specifically, we investigated the possibility that Tregs exhibited
suppression of innate cells by regulating the expression of MCP-1,
which is secreted by islet cells and is responsible for macrophage/
neutrophil recruitment [33,34]. Islet allografts were harvested at
the time of rejection in the Treg-untreated group and at day 21
post-transplantation in the Treg-treated group. RT-PCR analysis
showed that the level of MCP-1 gene transcription in Treg-treated
animals was reduced by 71% compared with Treg-untreated
animals (Fig. 7A). To test the direct effect of Tregs on MCP-1
production by islets, Tregs were co-cultured with freshly isolated
single islet cells in vitro. Consistent with the in vivo findings, Tregs
reduced MCP-1 transcription in the cultured islet cells (Fig. 7B).
In contrast, autologous Teffs co-cultured with islet cells had no
effect on MCP-1 expression (Fig. 7B). Flow cytometric analysis
confirmed that Tregs significantly decreased the number of MCP-1
positive cells in islet cells (Fig. 7C and F) and the expression of
MCP-1 by islet cells during co-culture with Tregs (Fig. 7D and E).
Interestingly, when the cytokine profile was analyzed in the sera of
Treg-treated animals, IFN-c was remarkably increased while IL-4
was significantly decreased (Fig. 8). Compared with controls, IL-8
was significantly elevated in serum of islet-transplanted hu-NSG
mice (Fig. 8).
Figure 5. Adoptive transfer of ex vivo expanded Tregs protects human islet allograft from rejection. (A) Percentage graft survival in hu-
NSG mice with or without Treg-treatments (n = 15 for islets alone group; n = 10 for Tregs-treated group; Log-rank test, p = 0.0004). (B) Histological
examination of islet grafts determined by immunostaining with antibodies for human antigens: insulin (brown), CD11b (green), CD66b (red), and CD4
(green). Nuclei were stained with DAPI (blue). Tissues were harvested at the time of islet allograft rejection in Tregs-untreated animals and at day 21
post-islet transfer in Treg-treated animals. (C) Quantitative data analysis of islet graft immunostaining. Data represent results from three individual
mice per group. (D) Identification of Tregs in the islet grafts. The harvested grafts were double-stained with FITC-conjugated CD4 (green) and TRITC-
conjugated FoxP3 (red). CD4/FoxP3 double-positive cells are shown by yellow colour. Inset images show enlarged area indicated by a white arrow.
Black arrow indicates islets grafts. **: p,0.01. Scale bar: 50 mm.
doi:10.1371/journal.pone.0090387.g005
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Discussion
The data presented here show that hu-NSG mice develop a
functional human immune system [26,29], and for the first time
we demonstrate the utility of hu-NSG mice for studying innate
immune responses to human islet allografts. Our study provides
evidence that ex vivo expanded human Tregs delay human islet
allograft rejection in hu-NSG mice, via a mechanism involving
reduced expression of MCP-1 by engrafted islets and inhibition of
infiltration by macrophages, neutrophils and CD4+ T cells.
Although immunodeficient mice allow engraftment of human
hematopoietic stem cells, it has not yet been possible to achieve
completely normal human hematopoiesis in any of the currently
available immunodeficient mouse strains [28,29]. The hu-NSG
mice generated in this study were approximately 30% chimeric
with human cells (CD45+ cells) including T- and B-cells and
subsets of various immune cells that are present in the spleen: these
Figure 6. Tregs accumulate in the draining lymph nodes and inhibit CD4
+ T cells in the draining lymph nodes and spleen. (A) The
absolute number of CD4+CD25+FoxP3+ cells in the draining lymph nodes and spleens, at the time of graft rejection (islets alone group) or at day 21
post-islet transfer (islets+Tregs group) was determined by flow cytometry. (B) Percentage of cells positive for human CD4 in draining lymph nodes
and spleens from (A). (C) Data are representative dot plots from three independent experiments. Plotted lines represent the mean (n = 5). **: p,0.01.
dLN: draining lymph nodes. Post-tx: post islet transfer.
doi:10.1371/journal.pone.0090387.g006
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include Tregs (CD4
+CD25+FoxP3+), monocytes/macrophages
(CD14+), DC (CD11c+) and NK cells (CD56+CD16+), indicating
reconstitution of human lymphohematopoiesis in these mice. We
noted human CD3 T cells engraftment in hu-NSG mice 12-16
weeks after CD34+ cell transfer, which was earlier than other
reports [35]. This may be due to differences in experimental
conditions and protocols used to engraft human stem cells,
including the choice of recipient age and source of human CD34+
cells [35].
The engrafted human T cells in our system were able to
produce cytokines including IL-2, TNF-a, TNF-b, IL-8 and IL-1b
and to respond to polyclonal CD3/CD28 stimulation, although
less efficiently than in adult blood, suggesting partial function of
engrafted T cells [26,29–31,36,37]. Confirming published work
[26,30,31,36–38], an impaired B cell response was also observed
Figure 7. Tregs reduced MCP-1 production in vitro and in vivo. (A) MCP-1 expression in islet grafts at the time of rejection (islets alone group) or
at day 21 post-islet transfer (islets+Tregs group) was measured by real-time RT-PCR (n = 5). b-actin was used as the endogenous control. (B) The
expression of mRNA was analyzed by real-time RT-PCR in islet cells co-cultured with Tregs for three days. (C–D) Cumulative data (mean6 SD) for MCP-
1 expression in cultured islet cells. MFI: mean fluorescence intensity. (E–F) Representative plots from 4 independent experiments are shown. *:
p,0.05; **: p,0.01. Post-tx: post islet transfer.
doi:10.1371/journal.pone.0090387.g007
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in these animals, showing inefficient production of antigen-specific
IgG. This is believed to be due to defective interaction between
human B and T cells [26,30,31,36–38], resulting from a lack of
human leukocyte antigen (HLA) expression in the mouse thymus
[26,38]. This possibility has been supported by the improved
antigen-specific human T cell and antibody responses achieved
when human CD34+ cells were injected in immunodeficient mice
that expressed HLA molecules either by transgenesis [38,39] or
following transplantation of human thymus [40]. Nevertheless,
although NSG mice receiving CD34+ cells failed to develop
efficient antigen-specific immune responses [26,30,31,36,37], we
found that, following immunization, engrafted human T cells
responded to alloantigens, as shown by 3H-thymidine incorpora-
tion in an in vitro culture of CD4+ cells from the spleen. These
findings do not exclude the possibility that other antigen
recognition pathways exist [28], thus there remains a need to
assess the major histocompatiblity complex (MHC) restriction of
human T cells in this animal model.
The importance of the innate immune system is currently
poorly understood in this model of human allograft rejection. The
presence of C3d deposition and infiltration of macrophages
(CD11b+) and neutrophils (CD66b+) into rejecting islet allografts
in these animals supports the idea that our system might be useful
for the study of innate immune responses to allografts. This view is
further strengthened by the detection of human C3 in the sera of
the islet-transplanted hu-NSG mice generated in this study, which
we speculate was locally produced by infiltrating human inflam-
matory cells [41,42]. Indeed, local immune cell-derived produc-
tion of complement emerges as a key mediator of complement’s
impact on adaptive immune responses [42].
One of the advantages of CD34+ cells-reconstituted humanized
mice is that they lack graft-versus-host disease (GvHD) [43]. By
rendering mice diabetic before islet transplantation, we have been
able to monitor the islet allograft rejection spontaneously mediated
by hu-NSG mice, evidenced by raising blood glucose. This
contrasts with PBMC-reconstituted NSG (huPBL-NSG) mice,
which died from GvHD within the first 30 days and provided only
4-5 week window of opportunity of the human immune responses
[32]. As a consequence, in the huPBL-NSG mice, rejection is often
determined post-facto by histopathology, making the huPBL-NSG
mouse model difficult to use for interventional studies [32]. In
keeping with blood glucose data, histological examination showed
a significant human CD45+ leukocytes infiltrate and islet
destruction in islet allograft, suggesting human immune-mediated
rejection in our system. These data are inconsistent with the
experiments using human CD34+ cells-reconstituted Balb/
cRag22/2cc2/2 mice [44]. The explanation for this discrepancy
might lie in the difference in the mouse strains [45,46]. Indeed
NSG mice, with NOD (nobese diabetic) background, allow better
hematopoietic engraftment than do Balb/cRag22/2cc2/2 mice
because the NOD variant of signal regulatory protein-a (SIRP-a)
binds human CD47, whereas Balb/cRag22/2cc2/2 mouse SIRP-
a does not [18]. Binding of SIRP-a expressed on mouse
macrophages to human CD47 is critical for the development of
human hematopoiesis in vivo and Sirpa polymorphism has been
identified as a new genetic determinant of human hematopoietic
stem cell engraftment [18].
We have here tested for the first time the impact of ex vivo
expanded human Tregs on the innate immune responses to human
islet allograft in the humanized mice. Several groups have
developed an optimal protocol for expanding Tregs for therapeutic
use [47–49]. Tregs used in current study were expanded in the
presence of CD3/CD28 beads and rapamycin as we previously
published [14]. Rapamycin prevents outgrowth of contaminating
non-regulatory cells, enhances Treg survival and expands the most
stable subpopulation of Tregs [49]. In the current study, we
observed that in Tregs-treated group, islet rejection was delayed for
15 days. Histological analysis demonstrated that there was
significantly less infiltrating macrophages, neutrophils and CD4+
T cells with preservation of islet structure in the grafts from Treg-
treated animals, suggesting that suppressive properties of Tregs are
not limited to effects on T-cell responses but also include inhibition
of pathology mediated by cells of the innate immune system system
[50,51]. Our demonstration is in agreement with recent findings
suggesting that expanded human Tregs can prevent rejection of
porcine islet xenograft in huPBL-NSG mice [52] and human islet
allograft in PBMC-reconstituted Balb/cRag22/2cc2/2 mice [24].
Similar results were also observed in the study of capacity of Tregs
to interfere with the innate immune responses from other groups,
including ours [53], in murine models of infectious diseases [54],
skin transplantation [53] and islet engraftment [50]. Whether the
inhibition of CD4+ T cell recruitment to the islet allograft was due
to a direct effect of Tregs on T cells or the consequence of the
action of Tregs on the innate immune system, as recently suggested
[50], needs further investigation.
Our data also showed that Tregs detected by double staining of
CD4 and FoxP3 were not present in a large numbers in the graft
at day 21 post-transfer in Tregs-treated group, suggesting that they
may have had an initial effect on the islet, and then migrated to
draining lymph nodes [50] [24]. This speculation was confirmed
by our findings that the absolute numbers of Tregs was significantly
higher in draining lymph nodes, along with significant decrease of
CD4+ T cells in spleen and draining lymph nodes from Treg-
treated animals when compared with in Tregs-untreated animals.
In line with our findings, Tregs have been demonstrated to
sequentially migrate from the site of tissue inflammation to the
draining lymph nodes to suppress alloimmune responses in a
mouse islet allograft model [55].
The ability of Tregs to inhibit a range of immune responses and
target a variety of cells suggests that they use multiple different
effector mechanisms [56]. In our study, Tregs directly interacted
with pancreatic islets, in the absence of effect T-cells, and inhibited
the innate responses of islets for chemokine MCP-1 production in
vitro. Consistent with our in vitro data, adaptive transfer of Tregs
resulted in decreased expression of MCP-1 on islet graft in vivo.
This finding may partly explain the mechanism underlying
inhibiting of infiltration by Tregs in the graft. Furthermore,
elevated serum levels of IFN-c in the Tregs-treated animals suggest
the contribution of IFN-c to regulation of Tregs as previously
published [57], although additional work needs to be done to
Figure 8. Tregs regulate human cytokine production in islet-
transplanted hu-NSG mice. Sera were collected at the time of
rejection (islets alone group) or at day 21 post-islet transfer (islets+Tregs
group). Cytokines were measured by cytokine bead array (n = 3).
Control: sera from hu-NSG mice without islet transplant. **: p,0.01.
doi:10.1371/journal.pone.0090387.g008
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prove that IFN-c is essential to the delay of islet rejection [57].
IFN-c is secreted by Th1 cells and conventionally thought to be
responsible for driving cell-mediated immune responses. However,
in recent years the promoting effects of IFN-c on the development
of Th1-controlling Tregs has drawn attention from various groups
[58,59]. The early production of IFN-c by induced Tregs following
reencounter with antigen has been demonstrated to prevent the
initiation of aggressive immune responses, including graft rejec-
tion, by controlling T-cell effector mechanisms [60]. In contrast to
our findings, one report showed decreased IFN-c levels in the sera
from Tregs-treated mice [52]. The difference in IFN-c levels might
be the different type of human hematopoietic cells engrafted
through reconstitution with either CD34+ cells or PBMC [52]. In
addition, IL-4, which can up-regulate MCP-1 expression in a
variety of cells [61], was remarkably decreased in Treg-treated
animals. These data suggest that the balance between these two
cytokines might contribute to the regulation of cellular MCP-1
expression [62].
In conclusion, the present study provides evidence that ex vivo
expanded human Tregs prolong islet allograft survival via
inhibiting infiltration of macrophages, neutrophils and CD4+ T
cells possibly through a MCP-1-dependent mechanism. These
data may contribute to the development of clinical strategies for
the generation of Treg therapy to control human islet rejection.
Also, we reveal for the first time that CD34+ stem cells-
reconstituted NSG mouse model might offer a tool for pre-clinical
evaluation of human innate immune responses to human
allografts.
Supporting Information
Figure S1 Assessment of human T cell function in hu-
NSG mice. (A) Splenocytes from hu-NSG mice and PBMC from
healthy donors (AdPBMC) were stimulated with CD3/CD28
beads for 3 days. T cell function was determined by 3H-thymidine
uptake (n = 6). (B) Human CD4+ T cells isolated from hu-NSG
mice immunized with 107 PBMC (specific) were cultured with the
same PBMC and with third party PBMC for 5 days. T cell
function was assessed in MLRs (n = 3). The insert shows the
spleens from a representative immunized (left) and non-immu-
nized mouse (right).
(TIF)
Figure S2 Production of human immunoglobins by
human B cells in hu-NSG mice. (A) Human IgM and IgG
were determined by ELISA in sera from hu-NSG mice 12–16
weeks after CD34+ cell reconstitution and in supernatants of B
cells cultured in the presence of IL-2 and IL-21. (B) Keyhole
limpet haemocyanin (KLH)-specific human IgM or IgG were
determined in the sera from hu-NSG mice immunized with KLH.
Sera from non-immunized hu-NSG mice were used as control.
(n = 3). For the B cell culture, a representative result of three
independent cultures is shown. NSG: sera from NSG mice without
CD34+ cell reconstitution; Nil: supernatant from the B cell culture
in the absence of IL-2 and IL-21.
(TIF)
Figure S3 Assessment of grafted human islet in hu-NSG
mice. Human islet equivalents (IEQs, 3000–4000) were trans-
planted into the kidney capsule of chemically-induced diabetic
mice and blood glucose was measured. The islets were removed
via unilateral nephrectomy when establishment of normoglycemia
(blood glucose,13.8 mM) had been confirmed in hu-NSG mice
and at day 30 post-islet transfer in NSG mice. The function of
human islet grafts was evaluated by measuring blood glucose
levels. All mice returned rapidly to a hyperglycemic state. Data
shown are representative examples from 3 animals in each group.
STZ: streptozotocin.
(TIF)
Figure S4 The phenotype and functional analysis of ex
vivo expanded human Tregs. (A) Representative flow cyto-
metric analysis of the expression of CD25 and FoxP3 molecules by
Tregs (cells were gated on human CD4 expression). Data are from
one out of three independent experiments with Tregs derived from
three individual donors. (B) CFSE–labelled CD4+CD252 cells
(responders) were co-cultured with serial dilutions of expanded
autologous Tregs in the presence of anti-CD3/CD28 beads for 5
days. Flow cytometric analysis was performed to assess cellular
proliferation by CFSE dilution. (C) Quantitative analysis of Tregs
suppressive function. The data shown are representative of three
independent experiments.
(TIF)
Table S1 HLA typing.
(TIF)
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